AECOPD
Conditions
Interventions
Sponsors
Hospital of Chengdu University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
40 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients who meet the diagnosis of phlegm-heat congested lung syndrome of AECOPD and need systemic glucocorticoid administration; 2. COPD GOLD stage 3 or 4 (post-bronchodilator forced FEV1/FVC = 10), regardless of sex; 4. Expected survival time >= 30 days; 5. Patients and their families agree to participate and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Atypical bacterial infections, such as atypical pathogens and drug-resistant bacteria; 2. Complicated with a severe tumor, unstable coronary heart disease, abnormal liver and kidney function, cerebrovascular accident, and other diseases; 3. Other associated active or clinically significant respiratory diseases that have a significant impact on the study, such as active pulmonary tuberculosis, lung cancer, bronchiectasis, pulmonary hypertension, pulmonary interstitial disease, and other active lung diseases; 4. Severe hypertension, diabetes, peptic ulcer, and other glucocorticoids contraindications; 5. Patients who require invasive mechanical ventilation; 6. Pregnant, lactating, and menstrual women; 7. Patients with mental disorders who are unable to actively cooperate with treatment; 8. Patients with a history of allergies to related drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The dosage of systemic glucocorticoids (at which the CAT scores improve by 50%).; | — |
Secondary
| Measure | Time frame |
|---|---|
| Symptoms and quality of life scores during the follow up;Pulmonary function;Exercise tolerance;Symptoms scores;Length of hospital stay;Inflammatory indicators; | — |
Countries
China
Contacts
Public ContactChen Keling
School of Clinical Medicine, Chengdu University of TCM
Outcome results
None listed